JP2016500648A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016500648A5 JP2016500648A5 JP2015532963A JP2015532963A JP2016500648A5 JP 2016500648 A5 JP2016500648 A5 JP 2016500648A5 JP 2015532963 A JP2015532963 A JP 2015532963A JP 2015532963 A JP2015532963 A JP 2015532963A JP 2016500648 A5 JP2016500648 A5 JP 2016500648A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- peptide
- active ingredient
- conjugate according
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20120104173 | 2012-09-19 | ||
| KR20120104144 | 2012-09-19 | ||
| KR10-2012-0104144 | 2012-09-19 | ||
| KR10-2012-0104173 | 2012-09-19 | ||
| KR20120109216 | 2012-09-28 | ||
| KR10-2012-0109216 | 2012-09-28 | ||
| KR20120109207 | 2012-09-28 | ||
| KR10-2012-0109207 | 2012-09-28 | ||
| KR10-2013-0017169 | 2013-02-18 | ||
| KR20130017169 | 2013-02-18 | ||
| PCT/KR2013/008438 WO2014046478A1 (ko) | 2012-09-19 | 2013-09-17 | 세포 투과성 펩티드, 그를 포함한 컨쥬게이트 및 그를 포함한 조성물 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018109473A Division JP6697028B2 (ja) | 2012-09-19 | 2018-06-07 | 細胞透過性ペプチド、それを含んだコンジュゲート、及びそれを含んだ組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016500648A JP2016500648A (ja) | 2016-01-14 |
| JP2016500648A5 true JP2016500648A5 (enExample) | 2016-11-10 |
| JP6352923B2 JP6352923B2 (ja) | 2018-07-04 |
Family
ID=50341699
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015532963A Active JP6352923B2 (ja) | 2012-09-19 | 2013-09-17 | 細胞透過性ペプチド、それを含んだコンジュゲート、及びそれを含んだ組成物 |
| JP2018109473A Active JP6697028B2 (ja) | 2012-09-19 | 2018-06-07 | 細胞透過性ペプチド、それを含んだコンジュゲート、及びそれを含んだ組成物 |
| JP2020076850A Active JP7041187B2 (ja) | 2012-09-19 | 2020-04-23 | 細胞透過性ペプチド、それを含んだコンジュゲート、及びそれを含んだ組成物 |
| JP2022037094A Active JP7368522B2 (ja) | 2012-09-19 | 2022-03-10 | 細胞透過性ペプチド、それを含んだコンジュゲート、及びそれを含んだ組成物 |
| JP2023176669A Active JP7742390B2 (ja) | 2012-09-19 | 2023-10-12 | 細胞透過性ペプチド、それを含んだコンジュゲート、及びそれを含んだ組成物 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018109473A Active JP6697028B2 (ja) | 2012-09-19 | 2018-06-07 | 細胞透過性ペプチド、それを含んだコンジュゲート、及びそれを含んだ組成物 |
| JP2020076850A Active JP7041187B2 (ja) | 2012-09-19 | 2020-04-23 | 細胞透過性ペプチド、それを含んだコンジュゲート、及びそれを含んだ組成物 |
| JP2022037094A Active JP7368522B2 (ja) | 2012-09-19 | 2022-03-10 | 細胞透過性ペプチド、それを含んだコンジュゲート、及びそれを含んだ組成物 |
| JP2023176669A Active JP7742390B2 (ja) | 2012-09-19 | 2023-10-12 | 細胞透過性ペプチド、それを含んだコンジュゲート、及びそれを含んだ組成物 |
Country Status (8)
| Country | Link |
|---|---|
| US (4) | US9902945B2 (enExample) |
| EP (3) | EP2899200B1 (enExample) |
| JP (5) | JP6352923B2 (enExample) |
| KR (3) | KR102362341B1 (enExample) |
| CN (3) | CN110074997B (enExample) |
| ES (2) | ES2956510T3 (enExample) |
| TW (3) | TWI678374B (enExample) |
| WO (1) | WO2014046478A1 (enExample) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104507961B (zh) | 2012-05-11 | 2018-08-14 | 珍白斯凯尔有限公司 | 抗炎性肽及包含其的组合物 |
| WO2013169077A1 (ko) | 2012-05-11 | 2013-11-14 | 주식회사 카엘젬백스 | 악액질 예방 또는 치료용 조성물 |
| ES2981865T3 (es) | 2012-07-11 | 2024-10-10 | Gemvax & Kael Co Ltd | Conjugado que comprende un péptido de penetración celular y composiciones que comprenden el mismo |
| US20150125438A1 (en) | 2012-07-20 | 2015-05-07 | Sang Jae Kim | Anti-Inflammatory Peptides and Composition Comprising the Same |
| CN104981478B (zh) * | 2012-09-19 | 2019-02-22 | 珍白斯凯尔有限公司 | 细胞穿透肽、包含该肽的缀合物、及包含该缀合物的组合物 |
| WO2014046481A1 (ko) | 2012-09-19 | 2014-03-27 | 주식회사 카엘젬백스 | 세포 투과성 펩티드, 그를 포함한 컨쥬게이트 및 그를 포함한 조성물 |
| TWI616530B (zh) * | 2012-09-19 | 2018-03-01 | 傑姆維克斯＆凱爾有限公司 | 穿膜胜肽以及包含該胜肽之共軛物及組成物（一） |
| CN110074997B (zh) | 2012-09-19 | 2022-07-08 | 珍白斯凯尔有限公司 | 细胞穿透肽、包含该肽的缀合物、及包含该缀合物的组合物 |
| US9907838B2 (en) | 2013-04-19 | 2018-03-06 | Gemvax & Kael Co., Ltd. | Composition and methods for treating ischemic damage |
| JP6059405B2 (ja) | 2013-06-07 | 2017-01-11 | ジェムバックス アンド カエル カンパニー，リミティド | 癌の免疫学的治療に有用な生物学的マーカー |
| WO2014204281A1 (ko) | 2013-06-21 | 2014-12-24 | 주식회사 카엘젬백스 | 호르몬 분비 조절제, 이를 포함하는 조성물, 및 이를 사용한 호르몬 분비 조절 방법 |
| ES2773296T3 (es) | 2013-10-23 | 2020-07-10 | Gemvax & Kael Co Ltd | Composición para tratar y prevenir la hiperplasia prostática benigna |
| KR102359396B1 (ko) | 2013-11-22 | 2022-02-08 | 주식회사 젬백스앤카엘 | 혈관 신생 억제 활성을 가지는 펩티드 및 이를 포함하는 조성물 |
| US11058744B2 (en) | 2013-12-17 | 2021-07-13 | Gemvax & Kael Co., Ltd. | Composition for treating prostate cancer |
| JP6420459B2 (ja) * | 2014-04-11 | 2018-11-07 | ジェムバックス アンド カエル カンパニー，リミティド | 線維症抑制活性を有するペプチド及びこれを含む組成物 |
| CN106659149B (zh) | 2014-04-30 | 2020-05-19 | 珍白斯凯尔有限公司 | 用于器官、组织或细胞移植的组合物、试剂盒和移植方法 |
| KR102413243B1 (ko) | 2014-12-23 | 2022-06-27 | 주식회사 젬백스앤카엘 | 안질환 치료 펩티드 및 이를 포함하는 안질환 치료용 조성물 |
| JP6751097B2 (ja) | 2015-02-27 | 2020-09-02 | ジェムバックス アンド カエル カンパニー，リミティド | 聴力損傷予防用ペプチド及びそれを含む組成物 |
| KR102911237B1 (ko) | 2015-05-26 | 2026-01-13 | 주식회사 젬백스앤카엘 | 신규 펩티드 및 이를 포함한 조성물 |
| KR101647804B1 (ko) * | 2015-06-24 | 2016-08-11 | 한국과학기술연구원 | 신규 세포투과 펩타이드 및 이의 용도 |
| EP3318265B1 (en) | 2015-07-02 | 2021-08-18 | Gemvax & Kael Co., Ltd. | Peptide having anti-viral effect and composition containing same |
| US10858397B2 (en) | 2015-08-28 | 2020-12-08 | The Medical College Of Wisconsin, Inc. | Peptide inhibitors of telomerase translocation and therapeutic uses thereof |
| EP4272829A3 (en) | 2016-04-07 | 2024-01-17 | Gemvax & Kael Co., Ltd. | Peptide having effects of increasing telomerase activity and extending telomere, and composition containing same |
| KR101710186B1 (ko) * | 2016-09-01 | 2017-03-10 | (주)에이씨티 | 6-아미노헥사노산 유도체 및 그 유도체를 함유하는 광반응성 화장료 조성물 |
| KR101843830B1 (ko) * | 2016-09-27 | 2018-04-02 | (주)라온크리에이트 | 피부 상태 개선 장치 및 그의 사용 방법 |
| CN107168012A (zh) * | 2017-07-11 | 2017-09-15 | 深圳市华星光电技术有限公司 | 一种彩色光刻胶及其制备方法 |
| JP7262105B2 (ja) | 2019-03-29 | 2023-04-21 | 国立研究開発法人理化学研究所 | 細胞透過性配列を有するポリペプチド及びそれを含む組成物 |
| CN118754948A (zh) * | 2020-09-03 | 2024-10-11 | 深圳厚存纳米药业有限公司 | 一种多肽及其多肽复合物纳米粒、核酸疫苗和应用 |
| CN117836310A (zh) | 2021-04-15 | 2024-04-05 | 万可真株式会社 | 细胞穿透肽、抗癌肽和包括其的用于预防或治疗癌症的药物组合物 |
| KR102713418B1 (ko) * | 2021-07-27 | 2024-10-07 | ㈜에빅스젠 | 세포막 투과 펩티드 및 이를 포함하는 세포내 전달체 |
| KR102415717B1 (ko) * | 2021-12-29 | 2022-07-05 | 주식회사 펩스젠 | 혈액뇌장벽 투과능을 가지는 신규한 펩타이드 및 이의 용도 |
| WO2023128122A1 (ko) * | 2021-12-29 | 2023-07-06 | 주식회사 펩스젠 | 혈액뇌장벽 투과능을 가지는 펩타이드 및 이의 용도 |
| KR102541402B1 (ko) * | 2022-02-18 | 2023-06-14 | 주식회사 레메디 | 아토피 피부염 예방 또는 치료 활성을 가지는 펩타이드 |
| WO2024117321A1 (ko) * | 2022-12-01 | 2024-06-06 | ㈜에빅스젠 | 세포막 투과 펩티드 및 이를 포함하는 세포내 전달체 |
| CN119552212B (zh) * | 2025-01-26 | 2025-04-25 | 杭州康源食品科技有限公司 | 一种具有降尿酸活性的三肽lfp及其应用 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7585622B1 (en) * | 1996-10-01 | 2009-09-08 | Geron Corporation | Increasing the proliferative capacity of cells using telomerase reverse transcriptase |
| EP0841396B2 (en) * | 1996-10-01 | 2012-04-11 | Geron Corporation | Human telomerase catalytic subunit |
| US6093809A (en) * | 1996-10-01 | 2000-07-25 | University Technology Corporation | Telomerase |
| US6475789B1 (en) * | 1996-10-01 | 2002-11-05 | University Technology Corporation | Human telomerase catalytic subunit: diagnostic and therapeutic methods |
| US6610839B1 (en) * | 1997-08-14 | 2003-08-26 | Geron Corporation | Promoter for telomerase reverse transcriptase |
| US7030211B1 (en) | 1998-07-08 | 2006-04-18 | Gemvax As | Antigenic peptides derived from telomerase |
| US7078491B1 (en) | 2000-09-21 | 2006-07-18 | Amgen Inc. | Selective binding agents of telomerase |
| US7294708B2 (en) * | 2002-05-31 | 2007-11-13 | Beijing Institute Of Biotechnology | Telomerase reverse transcriptase fragments and uses thereof |
| US8128908B2 (en) | 2004-04-30 | 2012-03-06 | University Of Florida Research Foundation, Inc. | Nanoparticles and their use for multifunctional bioimaging |
| EP1994942A1 (en) * | 2007-05-25 | 2008-11-26 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Pharmaceutical compositions comprising telomerase, and uses thereof |
| US8362209B2 (en) | 2007-08-23 | 2013-01-29 | University Of Medicine And Dentistry Of New Jersey | Telomerase reverse transcriptase variant |
| UY31361A1 (es) * | 2007-09-25 | 2009-04-30 | Vacunas y componentes para inhibir celulas microbianas | |
| HUE030984T2 (en) * | 2008-06-16 | 2017-06-28 | Mediolanum Farm S P A | Antitumor immunotherapy |
| US8252282B2 (en) * | 2008-06-19 | 2012-08-28 | University Of Medicine & Dentistry Of New Jersey | Nuclear telomerase reverse transcriptase variant |
| IT1393509B1 (it) * | 2008-07-08 | 2012-04-27 | Advanced Accelerator Applications S A | Peptidi e loro uso come carrier in cellule cancerose |
| WO2010037395A2 (en) | 2008-10-01 | 2010-04-08 | Dako Denmark A/S | Mhc multimers in cancer vaccines and immune monitoring |
| KR101169030B1 (ko) | 2009-01-21 | 2012-07-26 | 애니젠 주식회사 | 신규한 세포막 투과 도메인 및 이를 포함하는 세포내 전달 시스템 |
| PL2536830T3 (pl) * | 2010-02-16 | 2020-02-28 | Ultimovacs As | Polipeptydy |
| CN104507961B (zh) | 2012-05-11 | 2018-08-14 | 珍白斯凯尔有限公司 | 抗炎性肽及包含其的组合物 |
| ES2981865T3 (es) * | 2012-07-11 | 2024-10-10 | Gemvax & Kael Co Ltd | Conjugado que comprende un péptido de penetración celular y composiciones que comprenden el mismo |
| US20150125438A1 (en) | 2012-07-20 | 2015-05-07 | Sang Jae Kim | Anti-Inflammatory Peptides and Composition Comprising the Same |
| US20170327802A1 (en) | 2012-07-20 | 2017-11-16 | Gemvax & Kael Co., Ltd. | Anti-Inflammatory Peptides and Composition Comprising the Same |
| WO2014046481A1 (ko) | 2012-09-19 | 2014-03-27 | 주식회사 카엘젬백스 | 세포 투과성 펩티드, 그를 포함한 컨쥬게이트 및 그를 포함한 조성물 |
| CN104981478B (zh) | 2012-09-19 | 2019-02-22 | 珍白斯凯尔有限公司 | 细胞穿透肽、包含该肽的缀合物、及包含该缀合物的组合物 |
| CN110074997B (zh) * | 2012-09-19 | 2022-07-08 | 珍白斯凯尔有限公司 | 细胞穿透肽、包含该肽的缀合物、及包含该缀合物的组合物 |
| JP6059405B2 (ja) | 2013-06-07 | 2017-01-11 | ジェムバックス アンド カエル カンパニー，リミティド | 癌の免疫学的治療に有用な生物学的マーカー |
| KR102224965B1 (ko) | 2013-07-12 | 2021-03-09 | 주식회사 젬백스앤카엘 | 세포 투과성 펩티드 및 이를 포함하는 컨쥬게이트 |
| WO2017066349A1 (en) | 2015-10-13 | 2017-04-20 | Symic Ip, Llc | Ve-cadherin binding bioconjugate |
| CN106749537A (zh) * | 2017-02-04 | 2017-05-31 | 北京大学第医院 | 一种多肽及其作为siRNA递送载体的应用 |
-
2013
- 2013-09-17 CN CN201910066919.3A patent/CN110074997B/zh active Active
- 2013-09-17 CN CN201380057740.2A patent/CN104837859B/zh active Active
- 2013-09-17 JP JP2015532963A patent/JP6352923B2/ja active Active
- 2013-09-17 ES ES20172569T patent/ES2956510T3/es active Active
- 2013-09-17 ES ES13838181T patent/ES2802253T3/es active Active
- 2013-09-17 KR KR1020157009509A patent/KR102362341B1/ko active Active
- 2013-09-17 EP EP13838181.9A patent/EP2899200B1/en active Active
- 2013-09-17 WO PCT/KR2013/008438 patent/WO2014046478A1/ko not_active Ceased
- 2013-09-17 CN CN201910066931.4A patent/CN110092817B/zh active Active
- 2013-09-17 EP EP23177458.9A patent/EP4230644A3/en active Pending
- 2013-09-17 EP EP20172569.4A patent/EP3736282B1/en active Active
- 2013-09-17 TW TW107142413A patent/TWI678374B/zh active
- 2013-09-17 TW TW107100939A patent/TWI655204B/zh active
- 2013-09-17 KR KR1020227004140A patent/KR102544207B1/ko active Active
- 2013-09-17 US US14/429,637 patent/US9902945B2/en active Active
- 2013-09-17 KR KR1020237019231A patent/KR102578890B1/ko active Active
- 2013-09-17 TW TW102133731A patent/TWI655287B/zh active
-
2018
- 2018-01-12 US US15/869,518 patent/US10822595B2/en active Active
- 2018-06-07 JP JP2018109473A patent/JP6697028B2/ja active Active
-
2020
- 2020-04-23 JP JP2020076850A patent/JP7041187B2/ja active Active
- 2020-09-25 US US17/032,781 patent/US11773381B2/en active Active
-
2022
- 2022-03-10 JP JP2022037094A patent/JP7368522B2/ja active Active
-
2023
- 2023-08-17 US US18/451,280 patent/US20240084273A1/en active Pending
- 2023-10-12 JP JP2023176669A patent/JP7742390B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016500648A5 (enExample) | ||
| JP2016500513A5 (enExample) | ||
| JP2015530404A5 (enExample) | ||
| JP2015530358A5 (enExample) | ||
| van der Meel et al. | Ligand-targeted particulate nanomedicines undergoing clinical evaluation: current status | |
| Altai et al. | Affibody-derived drug conjugates: Potent cytotoxic molecules for treatment of HER2 over-expressing tumors | |
| Wyatt et al. | Applications of pHLIP technology for cancer imaging and therapy | |
| Kang et al. | A brain tumor-homing tetra-peptide delivers a nano-therapeutic for more effective treatment of a mouse model of glioblastoma | |
| Ruan et al. | Stapled RGD peptide enables glioma-targeted drug delivery by overcoming multiple barriers | |
| Chakraborti et al. | Self-assembly of ferritin: structure, biological function and potential applications in nanotechnology | |
| Belletti et al. | Protein cage nanostructure as drug delivery system: magnifying glass on apoferritin | |
| HRP20201973T1 (hr) | Ligandi modificirani kružnom permutacijom kao agonisti i antagonisti | |
| Bhushan et al. | Ferritin nanocages: a novel platform for biomedical applications | |
| HRP20190799T1 (hr) | Imunocitokini na bazi il-15 i sushi domene il-15r alfa | |
| Costantini et al. | Update: peptide motifs for insertion of radiolabeled biomolecules into cells and routing to the nucleus for cancer imaging or radiotherapeutic applications | |
| JP2011037872A5 (enExample) | ||
| WO2013056132A3 (en) | Porous nanoparticle-supported lipid bilayers (protocells) for targeted delivery including transdermal delivery of cargo and methods thereof | |
| TN2015000177A1 (en) | Anti-ceacam5 antibodies and uses thereof | |
| JP2010514779A5 (enExample) | ||
| HRP20121016T1 (hr) | Sredstva i postupci za upravljanje interferencijom proteina | |
| JP2014526881A5 (enExample) | ||
| JP2015522264A5 (enExample) | ||
| RU2016140214A (ru) | Адресное воздействие на устойчивый к трастузумабу her2+ рак молочной железы посредством her3-нацеленных наночастиц | |
| Singh et al. | DNA nanobots–emerging customized nanomedicine in oncology | |
| JP2016523558A5 (enExample) |